Handelsavisen
prelaunch
Companies Healthcare 054670.KQ
05
054670.KQ KOSDAQ Pharmaceuticals

054670.Kq

$5 770,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
1,41 %
Op margin
5,8 %
ROE
10,9 %
Net margin
7,5 %
Debt / equity
0,71
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
10,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 054670.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 054670.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a debt-to-equity ratio of 0.71, indicating a moderate level of leverage relative to its equity base. Its current ratio of 1.55 suggests that it has sufficient short-term assets to cover its short-term liabilities, though its liquidity position is assessed as medium due to negative net cash after subtracting total debt. The company's free cash flow is negative at -32.9 billion KRW, primarily driven by capital expenditures of -51.1 billion KRW, which may signal ongoing investment in infrastructure or expansion.

    Profitability metrics show a return on equity (ROE) of 10.9% and a return on assets (ROA) of 5.63%, both of which are key indicators of the company's efficiency in generating returns from its equity and total assets. These figures suggest that the company is performing above the industry median in terms of ROE, though the ROA is in line with the industry average.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic breakdown. This lack of diversification may expose the company to higher risk if demand for its products fluctuates in its primary market. The absence of segment or geographic data limits the ability to assess the company's exposure to different markets or product lines.

    Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's capital expenditures are expected to remain high, which may impact its free cash flow and liquidity in the near term. The company's operating cash flow of 5.06 billion KRW is relatively modest compared to its capital outlays, which may necessitate continued reliance on debt or equity financing to fund its operations.

    The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could limit the company's ability to fund operations without external financing. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares, indicating no imminent threat of share dilution.

    Recent filings and transcripts do not indicate any material events or strategic shifts that would significantly alter the company's financial or operational outlook. The company's financial performance appears to be in line with its historical trends, with no major disruptions or opportunities identified in the latest disclosures.

    Key takeaways
    • The company has a moderate debt-to-equity ratio of 0.71, indicating a balanced capital structure.
    • The company's ROE of 10.9% is strong, suggesting efficient use of equity to generate returns.
    • Free cash flow is negative at -32.9 billion KRW, primarily due to high capital expenditures.
    • The company's liquidity is assessed as medium, with a current ratio of 1.55 but negative net cash after debt.
    • The company's risk profile is characterized by medium liquidity risk and low dilution risk.
    • No significant growth or decline in revenue is expected in the next fiscal year.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $5 770,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $139.95B
    Net cash
    -$79.98B
    Current ratio
    1.6
    Debt / equity
    0.7
    ROA
    5.6%
    ROE
    10.9%
    Cash conversion
    33.0%
    CapEx / revenue
    -25.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin5,8 %Above median
    Net Margin7,5 %Above median
    ROE10,9 %Above P75
    Capex / Rev-25,2 %Bottom quartile
    D/E0,71Bottom quartile
    Cash Conv0,33Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 054670.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    054670.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage